DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

BTIG lowered the firm’s price target on DexCom (DXCM) to $107 from $120 and keeps a Buy rating on the shares as part of a broader research note ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

Some stocks are lagging the market for good reasons -- because their businesses look shaky and their prospects uncertain.

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

The stock's fall snapped a two-day winning streak.

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...